Evidence map›Paper›PMID 39888448›Full record

ArticleActa diabetologica2025

Sarcopenia in independent oldest-old individuals treated for diabetes, with or without metformin: a case-control study.

Maísa Braga Aguiar, Solomon Kim, Adriana Bruscato Bortoluzzo, Ana Beatriz Di Tommaso, Maysa Seabra Cendoroglo, Gisele W B Colleoni

Abstract read
PubMed Publisher
In one paragraph

Article in Acta diabetologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maísa Braga AguiarDiscipline of Geriatrics and Gerontology, Paulista School of Medicine, Federal University of São Paulo, Rua dos Otonis, 863, Vila Clementino, São Paulo, SP, ZIP CODE 04025-002, Brazil.
Solomon KimDiscipline of Geriatrics and Gerontology, Paulista School of Medicine, Federal University of São Paulo, Rua dos Otonis, 863, Vila Clementino, São Paulo, SP, ZIP CODE 04025-002, Brazil.
Adriana Bruscato BortoluzzoInsper - Instituto de Ensino e Pesquisa, São Paulo, Brazil.
Ana Beatriz Di TommasoDiscipline of Geriatrics and Gerontology, Paulista School of Medicine, Federal University of São Paulo, Rua dos Otonis, 863, Vila Clementino, São Paulo, SP, ZIP CODE 04025-002, Brazil.
Maysa Seabra Cendoroglo *Discipline of Geriatrics and Gerontology, Paulista School of Medicine, Federal University of São Paulo, Rua dos Otonis, 863, Vila Clementino, São Paulo, SP, ZIP CODE 04025-002, Brazil.
Gisele W B Colleoni *Discipline of Geriatrics and Gerontology, Paulista School of Medicine, Federal University of São Paulo, Rua dos Otonis, 863, Vila Clementino, São Paulo, SP, ZIP CODE 04025-002, Brazil. gcolleoni@unifesp.br.ORCID http://orcid.org/0000-0002-7144-4878

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSarcopenia is a common condition in the elderly, especially in diabetics (DM). Metformin (MTF), known to reduce glucose levels, can also be a therapeutic intervention in age-related diseases, although it may contribute to muscle loss.

objectivesTo compare the prevalence of sarcopenia among elderly people treated for DM, with or without MTF, and non-diabetic patients (NDM) and evaluate whether there is an association between the use of MTF and the development of sarcopenia.

methods194 independent elderly people over 80 years old were analyzed. Sarcopenia was defined by handgrip (HG), calf circumference (CC), and gait speed (GS). Non-parametric statistical analysis and Kaplan-Meier survival curves were used.

resultsThe prevalence of DM was 24.7%, of which 56.25% used MTF. The median fasting blood glucose in the NDM and DM groups was 95 and 104 mg/dL. The median glycated hemoglobin in the NDM and DM groups was 5.7% and 6.4%. There was no statistical difference between the DM and NDM groups when comparing clinical characteristics, functionality, weight, physical tests, and mortality. The prevalence of sarcopenia was similar between NDM and DM (16.55% and 14.63%), with few cases of severe sarcopenia in both groups, without statistical differences. We did not find differences in the same variables when we analyzed NDM and DM using or not MTF. Survival curves showed no significant differences between patients with and without sarcopenia/severe sarcopenia.

conclusionsLong-lived people with well-controlled DM did not show significant differences concerning those without DM for the outcome of sarcopenia or death.

Indexed as

Diabetes MellitusDiabetes Mellitus, Type 2Hypoglycemic AgentsMetforminSarcopeniaAged, 80 and overBlood GlucoseCase-Control StudiesFemaleHand StrengthHumansMalePrevalenceBlood GlucoseHypoglycemic AgentsMetforminDiabetesMetforminOldest oldSarcopenia

Identifiers

PMID39888448

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.